Sökning: onr:"swepub:oai:lup.lub.lu.se:61596623-f0c1-475d-9288-9fe43d45015b" > 188Re-ZHER2:V2, a p...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 07208naa a2200829 4500 | |
001 | oai:lup.lub.lu.se:61596623-f0c1-475d-9288-9fe43d45015b | |
003 | SwePub | |
008 | 221116s2014 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:kth-157017 | |
009 | oai:DiVA.org:uu-211593 | |
024 | 7 | a https://lup.lub.lu.se/record/61596623-f0c1-475d-9288-9fe43d45015b2 URI |
024 | 7 | a https://doi.org/10.2967/jnumed.114.1401942 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-1570172 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2115932 URI |
040 | a (SwePub)lud (SwePub)kthd (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Altai, Mohamedu Uppsala universitet,Uppsala University,Enheten för biomedicinsk strålningsvetenskap4 aut0 (Swepub:uu)mohal988 |
245 | 1 0 | a 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors : preclinical assessment |
264 | c 2014-10-02 | |
264 | 1 | b Society of Nuclear Medicine,c 2014 |
500 | a QC 20141205 | |
520 | a UNLABELLED: Affibody molecules are small (7 kDa) nonimmunoglobulin scaffold proteins with favorable tumor-targeting properties. Studies concerning the influence of chelators on biodistribution of (99m)Tc-labeled Affibody molecules demonstrated that the variant with a C-terminal glycyl-glycyl-glycyl-cysteine peptide-based chelator (designated ZHER2:V2) has the best biodistribution profile in vivo and the lowest renal retention of radioactivity. The aim of this study was to evaluate (188)Re-ZHER2:V2 as a potential candidate for radionuclide therapy of human epidermal growth factor receptor type 2 (HER2)-expressing tumors.METHODS: ZHER2:V2 was labeled with (188)Re using a gluconate-containing kit. Targeting of HER2-overexpressing SKOV-3 ovarian carcinoma xenografts in nude mice was studied for a dosimetry assessment.RESULTS: Binding of (188)Re-ZHER2:V2 to living SKOV-3 cells was demonstrated to be specific, with an affinity of 6.4 ± 0.4 pM. The biodistribution study showed a rapid blood clearance (1.4 ± 0.1 percentage injected activity per gram [%ID/g] at 1 h after injection). The tumor uptake was 14 ± 2, 12 ± 2, 5 ± 2, and 1.8 ± 0.5 %IA/g at 1, 4, 24, and 48 h after injection, respectively. The in vivo targeting of HER2-expressing xenografts was specific. Already at 4 h after injection, tumor uptake exceeded kidney uptake (2.1 ± 0.2 %IA/g). Scintillation-camera imaging showed that tumor xenografts were the only sites with prominent accumulation of radioactivity at 4 h after injection. Based on the biokinetics, a dosimetry evaluation for humans suggests that (188)Re-ZHER2:V2 would provide an absorbed dose to tumor of 79 Gy without exceeding absorbed doses of 23 Gy to kidneys and 2 Gy to bone marrow. This indicates that future human radiotherapy studies may be feasible.CONCLUSION: (188)Re-ZHER2:V2 can deliver high absorbed doses to tumors without exceeding kidney and bone marrow toxicity limits. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng |
653 | a Animals | |
653 | a Antibodies/chemistry | |
653 | a Cell Line, Tumor | |
653 | a Chelating Agents/chemistry | |
653 | a Drug Evaluation, Preclinical | |
653 | a Female | |
653 | a Gluconates/chemistry | |
653 | a Humans | |
653 | a Mice | |
653 | a Mice, Nude | |
653 | a Oligopeptides/chemistry | |
653 | a Ovarian Neoplasms/drug therapy | |
653 | a Peptides/chemistry | |
653 | a Radiation Dosage | |
653 | a Radioisotopes/therapeutic use | |
653 | a Radiometry | |
653 | a Radiopharmaceuticals | |
653 | a Receptor, ErbB-2/chemistry | |
653 | a Rhenium/chemistry | |
653 | a Xenograft Model Antitumor Assays | |
653 | a HER2 | |
700 | 1 | a Wållberg, Helenau KTH,KTH Royal Institute of Technology,Proteinteknologi4 aut0 (Swepub:kth)u1527tt1 |
700 | 1 | a Honarvar, Hadisu Uppsala universitet,Uppsala University,Enheten för biomedicinsk strålningsvetenskap4 aut0 (Swepub:uu)hadho340 |
700 | 1 | a Strand, Joannau Uppsala universitet,Uppsala University,Enheten för biomedicinsk strålningsvetenskap4 aut0 (Swepub:uu)joast981 |
700 | 1 | a Orlova, Annau Uppsala universitet,Uppsala University,Plattformen för preklinisk PET4 aut0 (Swepub:uu)annaorlo |
700 | 1 | a Varasteh, Zohrehu Uppsala universitet,Uppsala University,Plattformen för preklinisk PET4 aut0 (Swepub:uu)zohva473 |
700 | 1 | a Sandström, Mattiasu Uppsala universitet,Uppsala University,Uppsala University Hospital,Enheten för medicinsk strålfysik,Enheten för nuklearmedicin och PET4 aut0 (Swepub:uu)masan637 |
700 | 1 | a Löfblom, Johnu KTH,KTH Royal Institute of Technology,Proteinteknologi4 aut0 (Swepub:kth)u1z7cgkl |
700 | 1 | a Larsson, Eriku Lund University,Lunds universitet,Medicinsk strålningsfysik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical Radiation Physics, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)radf-ela |
700 | 1 | a Strand, Sven-Eriku Lund University,Lunds universitet,Forskningsgruppen för Systemisk strålterapi,Forskargrupper vid Lunds universitet,Systemic Radiation Therapy Group,Lund University Research Groups4 aut0 (Swepub:lu)rafy-ses |
700 | 1 | a Lubberink, Marku Uppsala universitet,Uppsala University,Uppsala University Hospital,Enheten för nuklearmedicin och PET,Avdelningen för sjukhusfysik4 aut0 (Swepub:uu)marklubb |
700 | 1 | a Ståhl, Stefanu KTH,KTH Royal Institute of Technology,Proteinteknologi,Uppsala University, Sweden4 aut0 (Swepub:kth)u1svy8i4 |
700 | 1 | a Tolmachev, Vladimiru Uppsala universitet,Uppsala University,Enheten för biomedicinsk strålningsvetenskap4 aut0 (Swepub:uu)vladtolm |
710 | 2 | a Uppsala Universityb Enheten för biomedicinsk strålningsvetenskap4 org |
773 | 0 | t Journal of nuclear medicine : official publication, Society of Nuclear Medicined : Society of Nuclear Medicineg 55:11, s. 8-1842q 55:11<8-1842x 0161-5505x 1535-5667x 2159-662X |
773 | 0 | t Journal of Nuclear Medicined : Society of Nuclear Medicineg 55:11, s. 8-1842q 55:11<8-1842x 2159-662X |
856 | 4 | u http://dx.doi.org/10.2967/jnumed.114.140194x freey FULLTEXT |
856 | 4 | u http://jnm.snmjournals.org/content/55/11/1842.full.pdf |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:675121/FULLTEXT01.pdfx primaryx Raw objecty fulltext:postprint |
856 | 4 8 | u https://lup.lub.lu.se/record/61596623-f0c1-475d-9288-9fe43d45015b |
856 | 4 8 | u https://doi.org/10.2967/jnumed.114.140194 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-157017 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-211593 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.